Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Verified Market Research | PRODUCT CODE: 1620368

Cover Image

PUBLISHER: Verified Market Research | PRODUCT CODE: 1620368

Global Azithromycin Market Size By Type (Oral, Injectable, and Ophthalmic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geographic Scope And Forecast

PUBLISHED:
PAGES: 202 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 3950
PDF & Excel (5 User License)
USD 4850
PDF & Excel (Enterprise User License)
USD 7550

Add to Cart

Azithromycin Market Size And Forecast

Azithromycin Market size was valued at USD 6.98 Billion in 2024 and is projected to reach USD 10.71 Billion by 2031 , growing at a CAGR of 3.5% from 2024 to 2031. The increasing prevalence of bacterial infection is driving the growth of the Azithromycin Market. The Global Azithromycin Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Azithromycin Market Definition

Azithromycin is a class of drugs, that belongs to antibacterials antibiotics. It is an antibiotic that helps in treating bacterial infections. It is normally sold beneath the whole names Zithromax and Zmax. A doctor might impose azithromycin to treat mild-to-moderate infections of the lungs, sinuses, skin, and different body elements. It will resist harmful microorganisms from growing and may fight a large variety of microorganisms, together with several within the eubacteria family.

Azithromycin may be a macrolide antibiotic used to treat bacterial infections. it's one of the world's most popular antibiotics. The injectable sort of azithromycin is employed to treat bound bacterial infections, like respiratory disease, pneumonia, or ear infections. injectable azithromycin is typically given as an infusion into a vein over 60 minutes.

Azithromycin may be a macrolide antibiotic that's derived from Pediamycin. It works by inhibiting the translocation step in macromolecule synthesis by binding to ribosomal subunits in microorganisms which ends with the inhibition of bacterial growth. It is used for the treatment of infections caused by microorganisms like respiratory disease, pneumonia, sexually transmitted diseases, and different infection of the attention, skin, ear, and different metabolism infections. It can be conjointly utilized in the treatment of true bacteria avium advanced (MAC) infection.

The rise in the prevalence of bacterial infections, and therefore the increasing handiness of azithromycin tablets as generic and name medicine are the key factors that may drive the market growth. Also, growing tending expenditure, increasing importance of azithromycin as a prophylactic agent, and an increase in the investment by pharmaceutical corporations to accelerate analysis activities are the factors that may expand the Azithromycin Market.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Azithromycin Market Overview

The increasing prevalence of bacterial infection is driving the expansion of the Azithromycin Market. Azithromycin is the world's most popular antibiotic. It is verified to be extraordinarily economical and capable of remaining within the body tissue longer than other similar varieties. Companies are investing and investigating considerably within the Azithromycin marketplace for a new treatment, gap due to new markets.

COVID-19 wedged the worldwide offer chain of prescription drugs, touching the antibiotics market. However, several antibiotics were at first used to treat COVID-19 and are widely prescribed and studied because of the COVID-19 remedy. For instance, in March 2020, Pfizer declared positive information for exploitation of its azithromycin (Zithromax) drug, together with Plaquenil, in an exceeding coronavirus (COVID-19) test performed in France. There was a large demand for antibiotics throughout the COVID-19 pandemic, that conjointly wedged the studied market of antibiotics.

For instance, authority approval for preventing bacterial infections in individuals with HIV. However, at constant times, authority disapproval for many therapies due to risk issues associated is restraining the expansion of the Azithromycin Market. At present, azithromycin is approved for acute bacterial urinary tract infection, venereal ulceration malady, sinusitis, bacterial exacerbations of chronic clogging pneumonic malady community-acquired respiratory disease, sore throat, skin infections, and different conditions.

There is a huge and growing demand from rising markets. The demand for azithromycin is growing quickly in rising markets like China, India, Brazil, and Mexico due to the increasing incidence of infectious diseases as well as rising incomes and increasing tending infrastructure. This presents a large chance for drugmakers in operation during this market phase.

However, an increase in the incidence of bacterial resistance due to long-run administration of azithromycin and the effects related to azithromycins like nausea, abdominal pain, diarrhea, irregular heartbeat, severe lightheadedness, and eye issues are the factors that may hinder the market growth and an additional challenge the Azithromycin Market within the forecast period.

Global Azithromycin Market Segmentation Analysis

The Global Azithromycin Market is segmented on the basis of Type, Distribution Channel, And Geography.

Azithromycin Market, By Type

  • Oral
  • Injectable
  • Ophthalmic

Based on Type, the market is segmented into Oral, Injectable, and Ophthalmic. The Oral segment is dominating the market with the highest market share and is expected to grow substantially and dominate the global market during the forecast period.

Azithromycin Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies component is witnessing the highest market share with strong market growth during the forecast period in the global market. The Segment centers on the standing and opportunity for significant application value, market share, and growth valuation of each application.

Azithromycin Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Regional Analysis, the Global Azithromycin Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North America and Europe regions are dominating the Global Market with the highest market stake and are predicted to grow substantially and dominate the Global Azithromycin Market throughout the forecast period.

Key Players

  • The "Global Azithromycin Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
  • Pfizer, Akorn, Teva, Mylan, Zydus Pharmaceuticals, Sandoz, Wockhardt, Gland Pharma, Aurobindo Pharma, and CSPC Ouyi Pharmaceutical, Hainan Poly Pharm, Hainan Hailing Chemipharma Corporation, Anke Hengyi
  • . Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis.
Product Code: 11630

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL AZITHROMYCIN MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL AZITHROMYCIN MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porter Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL AZITHROMYCIN MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Oral
  • 5.3 Injectable
  • 5.4 Others

6 GLOBAL AZITHROMYCIN MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
  • 6.2 Hospital Pharmacies
  • 6.3 Retail Pharmacies
  • 6.4 Others

7 GLOBAL AZITHROMYCIN MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 The U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 The U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 The Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 The Middle East and Africa

8 GLOBAL AZITHROMYCIN MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 CSPC Ouyi Pharmaceutical
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Aurobindo Pharma
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Gland Pharma
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Wockhardt
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Sandoz
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Zydus Pharmaceuticals
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Mylan
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Teva
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Akorn
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Pfizer
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Related Research

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!